To date, 11 ICIs has been approved by FDA to target T cells via CTLA4 (ipilimumab (Yervoy®)) or PD1 (cemiplimab-rwlc (Libtayo), nivolumab (Opdivo®), and pembrolizumab (Key-truda®)), and target cancer cells and antigen-presenting cell in the tumor microenvironment via PDL1 (and durvalumab (Imfinzi®), avelumab (Bavencio®), and atezolizumab (Tecentriq)). This evidence concerns the gene CD274 and cancer.